[Treatment of small cell lung cancer].
The treatment of choice for limited small-cell lung cancer (SCLC) is platinum-based chemotherapy combined with early, concurrent thoracic radiotherapy with a hyperfractionated regimen. The standard chemotherapy for extensive SCLC in Japan is the combination of irinotecan and cisplatin. There are expectations for new and effective molecular-target-based drugs for SCLC.
Negoro
Shunichi
S
Dept. of Thoracic Oncology, Hyogo Medical Center for Adults, Akashi City, Japan.
D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D016019:Survival Analysis
D018943:Anthracyclines; D005047:Etoposide; D000077146:Irinotecan; C055866:amrubicin; D002945:Cisplatin; D002166:Camptothecin